Regeneron Pharmaceuticals

In operation since 1981, Genzyme Corporation is one of the leading biotechnology companies in the world. The company employs a staff of more than 12,000 people and manages over 85 locations in nearly 40 countries. It focuses on the areas of hematologic oncology, biosurgery, transplant, genetic diseases, and cardiometabolic and renal. Genzyme Corporation offers Fabrazyme, which is a solution for intravenous infusion. The company also provides Fabrazyme, Renagel, Renvela and Hectorol. It offers solutions for the medical and patient communities. In addition, Genzyme Corporation offers Synvisc, which is a viscosupplementation treatment for relieving knee pain associated with osteoarthritis. The company provides Sepra, which is a line of hyaluronic acid-based products.

Generation Bio Co, based in Cambridge, MA, is pioneering advancements in targeted therapeutics for T cell-driven autoimmune diseases through its innovative cell-targeted lipid nanoparticles (ctLNP) technology. This approach enables selective delivery of siRNA specifically to T cells, effectively modulating their function while preserving the integrity of the broader immune system. The company's mission is to unlock the full potential of siRNA therapeutics in T cells, aiming to create more potent and better-tolerated treatments for autoimmune conditions. With a dedicated and experienced team, Generation Bio is set to lead the next wave of targeted siRNA therapeutics, providing novel solutions for patients living with these challenging diseases. Generated from the website

Orbital Therapeutics, based in Cambridge, MA, is dedicated to advancing RNA medicines aimed at expanding access to innovative therapies for patients with various diseases. Their cutting-edge platform integrates RNA discovery and design, focusing on immune reprogramming to help restore health by delivering precise molecular instructions directly to immune cells. The company emphasizes a culture of collaboration and has assembled a team experienced in transitioning medicines from concept to clinical application. Through their comprehensive RNA platform, Orbital Therapeutics seeks to engineer durable therapies with the flexibility needed to effectively modulate disease outcomes. Generated from the website